Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
GOG 0225IRB 12-869 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4 Fallopian Tube, Gynecologic, Ovarian, Peritoneal
GOG 0264CC906 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary Fairview, Hillcrest, Main CampusRecurrent/Relapsed, Stage 2, Stage 3, Stage 4Phase 2Gynecologic, Ovarian
GOG 0281 15-481 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Fairview, Hillcrest, Main Campus Phase 2, Phase 3Ovarian, Peritoneal
GOG 300515-866 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrentand Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous EpithelialOvarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
JAN 1814 14-711 A Randomized, Open-Label Study Comparing the Combination of YONDELIS, and DOXIL/CAELYX,With DOXIL,/CAELYX, Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
MORAb-003-011 15-298 MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 2Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY004 16-360 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main Campus Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY005 16-395 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Fairview, Hillcrest, Main CampusRecurrent/RelapsedPhase 2, Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
NRG-GY007 16-877 A Phase I/II Study of Ruxolitnib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main CampusStage 3, Stage 4Phase 1, Phase 2Fallopian Tube, Gynecologic, Ovarian, Peritoneal

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.